Spero Therapeutics (SPRO) Total Non-Current Liabilities (2016 - 2022)

Spero Therapeutics (SPRO) has reported Total Non-Current Liabilities for 7 consecutive years, with $48.9 million the latest figure, recorded in Q4 2022.

• For the quarter ending Q4 2022, Total Non-Current Liabilities fell 40.39% year-over-year to $48.9 million; the trailing twelve-month figure through Dec 2022 stood at $48.9 million (down 40.39% YoY), and the FY2022 full-year result was $48.9 million, down 40.39% from the prior year.
• Total Non-Current Liabilities rose to $48.9 million in Q4 2022 per SPRO's latest filing, from $31.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $82.4 million in Q1 2022 and bottomed at $5.9 million in Q1 2018.
• Historically, Total Non-Current Liabilities has averaged $29.1 million across 5 years, with a median of $19.3 million in 2019.
• The sharpest annual moves came in 2020 and 2022: Total Non-Current Liabilities soared 145.69% in 2020, then slumped 40.39% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $12.9 million in 2018, then soared by 49.1% to $19.3 million in 2019, then surged by 41.46% to $27.3 million in 2020, then soared by 200.66% to $82.0 million in 2021, then plunged by 40.39% to $48.9 million in 2022.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $48.9 million, $31.9 million, and $27.6 million for Q4 2022, Q3 2022, and Q2 2022 respectively.